Using a covalent menin inhibitor as an approach against diabetes (and more) with Biomea Fusion's CEO

blonca9
Dec 18, 2023
1 min read

Updated: Dec 21, 2023

Thomas Butler describes Biomea's hypothesis of utilizing a covalent, irreversible menin inhibitor to promote beta cell proliferation in diabetes. He reviews Biomea's latest clinical data, and highlights the company's cancer programs.

Recent Posts

See All

CLAIRITY BREAST, an AI platform that predicts five-year breast cancer risk from routine mammograms, became the first such AI tool to receive FDA authorization for breast cancer prediction

Cullinan Therapeutics' CEO Nadim Ahmed covers last week's #ASCO25 data for zipalertinib in EGFRex20 insertion lung cancer, plus an in-depth conversation about bispecifics for autoimmune conditions

AI News: Artera presented data at #ASCO25 showing that its AI platform can identify prostate cancer patients most likely to benefit (or not benefit) from added androgen receptor inhibitor therapy

Using a covalent menin inhibitor as an approach against diabetes (and more) with Biomea Fusion's CEO

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight